Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exposure to Selective Serotonin Reuptake Inhibitors in Early Pregnancy and the Risk of Miscarriage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association between maternal weight gain and birth weight

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effect of weight maintenance on symptoms of knee osteoarthritis in obese patients: a twelve-month randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Experimental knee joint pain during strength training and muscle strength gain in healthy subjects: a randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Affective disorders in neurological diseases: a case register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jennie Laigaard
  • Tina Sørensen
  • Sophie Placing
  • Peter Holck
  • Camilla Fröhlich
  • Karen R Wøjdemann
  • Karin Sundberg
  • Anne-Cathrine Shalmi
  • Ann Tabor
  • Bent Nørgaard-Pedersen
  • Bent Ottesen
  • Michael Christiansen
  • Ulla M. Wewer
Vis graf over relationer

OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia.

METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age.

RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053).

CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia.

LEVEL OF EVIDENCE: II-2.

OriginalsprogEngelsk
TidsskriftObstetrics and Gynecology
Vol/bind106
Udgave nummer1
Sider (fra-til)144-9
Antal sider6
ISSN0029-7844
DOI
StatusUdgivet - jul. 2005

ID: 51786855